drugset / Trial / NCT07674823
Phase 1 Study Of KITE-753 in R/R B-Cell ALL
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
Timeline
- Start
- 2026-12-31
- Primary completion
- 2029-04-01
- Completion
- 2031-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KITE-753 | Cell therapy | — | — |